Gouty Arthritis Market Size 2020 Industry Overview Growth Analysis, Regional Demand, Future Scope and Forecast To 2026
SEATTLE, March 24, 2021, (PHARMIWEB) — Gouty arthritis is a medical condition in which uric acid crystals are deposited in the joints and lead to intense joint pain. Redness and swelling of joints and intense pain are some of the major factors of gouty arthritis. Untreated gouty arthritis may damage joints or kidneys as an excessive accumulation of uric acid crystals would lead to kidney stones, kidney failure.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1368
High prevalence of chronic diseases is expected to fuel the growth of the gouty arthritis market
Sometimes hypertension is often associated with gout. As per a study published in the Journal of Rheumatology in 2014, around 75% of gouty arthritis patient was reported to be suffering from hypertension. Therefore patients suffering from chronic disease are at high risk of developing gouty arthritis. A high prevalence of gouty arthritis is projected to drive the growth for the global gouty arthritis market. According to a study published in the British Medical Journal in 2017, the prevalence of gouty arthritis is 1% to 10% globally. Moreover, increasing consumption of high protein food around the globe and growing awareness amongst people for early treatment of disease are the other factors propelling the growth of the gouty arthritis market.
On the flip side, lack of awareness among the medical fraternity regarding effective treatment of the condition, especially in emerging economies is expected to hinder gouty arthritis market growth. For instance, there is different opinion on whether to use urate-lowering agents in acute gouty arthritis, urate-lowering agent lowers serum urate levels for the dissolution of urate crystals, which is done either by reducing the production of serum uric acid or by promoting its excretion. Also, high costs associated with treatment therapy in chronic gouty arthritis are projected to curb the growth of the gouty arthritis market.
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Gouty Arthritis Market Research Report: https://bit.ly/3vWArE8
Based on Drug Class
- Urate-Lowering Agents
Based On Gouty Types
- Acute gouty arthritis
- Chronic gouty arthritis
North America holds a dominant position in gouty arthritis market
Regional segmentation of the gouty arthritis market by Coherent Market Insights consists of North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is projected to dominate gouty arthritis market, and this can be attributed to high prevalence of gouty arthritis in the U.S. According to Centre for Disease Control and Prevention (CDC), an estimated 54.4 million patients annually suffered from some form of arthritis from 2013 – 2015, in which gouty arthritis carries significant share. According to clinical guidelines for gout published in Annals of Internal Medicine in 2017, about 3.9% of U.S. adults older than 20 years reported about gout at least once in a lifetime. Furthermore, the growing geriatric population base rate is also driving the growth of the market, as patients above 40 years of age are more prone to gouty arthritis. Additionally, the advent of new and effective therapies to treat gouty arthritis is further expected to fuel the growth of the gouty arthritis market. For instance, in 2015, Astra Zeneca received FDA approval for novel molecule lesinurad (Zurampic), lesinurad is a urate transport inhibitor which inhibits URAT1, a protein responsible for reabsorption of uric acid in kidneys, given in combination with xanthine oxidase inhibitor helps achieve target serum uric acid level. Asia Pacific region is gaining significant traction in this market, due to rising number of patients suffering from chronic diseases such as diabetes and cardiovascular disease or chronic kidney disease, which are rising incrementally as stated by WHO factsheet 2012, this is owing to fact that around 75% hypertensive patients had gouty arthritis as study published in Journal of Rheumatology in 2014.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/gouty-arthritis-market-1368
Major players operating in the gouty arthritis market include AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Novartis AG; Savient Pharmaceuticals, GlaxoSmithKline plc, Merck& Co. Inc., Teijin Pharma Ltd., Regeneron Pharmaceuticals, JW Pharmaceutical Corporation, and Nippon Chemiphar Co. Ltd.
- In August 2017, the FDA approved the first fixed-dose combination called Duzallo (Ironwood Pharmaceuticals) of lesinurad with allopurinol to treat hyperuricemia in patients with uncontrolled gout. Duzallo is a one a day combination of oral treatment.
- In 2015, Prasco Laboratories and Takeda Pharmaceutical Inc. entered into a distribution and supply agreement for the rights to distribute Colchicine Tablets, USP, which is a generic version of Colrycs, colchicine brand by Takeda Pharmaceutical Inc., this would strengthen the distribution for colchicine and improve accessibility.
- Novartis in 2013 received European Commission approval for Ilaris in the treatment of acute gouty arthritis for patients who suffer from frequent attacks of gouty arthritis and are contraindicated to use other treatment options. Illaris is the first biologic product to be used in gouty arthritis in Europe.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1368
Table of Content
Global Gouty Arthritis Market Research Report
Section 1: Global Gouty Arthritis Industry Overview
Section 2: Global Economic Impact on Gouty Arthritis Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Gouty Arthritis Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Gouty Arthritis Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire